Healthcare  |  Drug Manufacturers—General
110.02 0.0 0.0%
Stock Price | Nov. 15, 2019, 4 p.m.
Bid: 0.0
Ask: 0.0
Prev. Close: 110.02
52 Week Low: 58.59
52 Week High: 110.7
PE Ratio: 13.549261
Dividend Yield: 0.0%

Company Summary

Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Recent acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.

Read more Read less

Recently Viewed Tickers

Free 4 Stocks to Buy Now for 2016

4 years ago